Lian Yong Chen
Chairman presso OCUMENSION THERAPEUTICS
Patrimonio netto: 4 M $ in data 31/03/2024
Profilo
Lian Yong Chen founded Frontline Bioventures in 2012, where he worked as Managing Partner from 2012 to 2017.
Dr. Chen also currently works at 6 Dimensions Capital, as CEO & Founding Partner, Tongrun Biomedicine (Shanghai) Co., Ltd., as Chairman from 2018, Ocumension Therapeutics, as Non-Executive Chairman from 2021, Cutia Therapeutics (Shanghai) Co., Ltd., as Chairman, Cutia Therapeutics, as Non-Executive Chairman from 2022, Neusoft Medical Systems Co., Ltd., as Non-Executive Director from 2021, Neusoft Xikang Holdings, Inc., as Non-Executive Director from 2019, TenNor Therapeutics Suzhou Ltd., as Director, Engine Biosciences Pte Ltd., as Director, 111, Inc., as Director from 2019, Hua Medicine Technology (Hong Kong) Ltd., as Director from 2015, Hua Medicine (Shanghai) Co., Ltd., as Director from 2016, and China Life Sciences Access Fund LP, as General Partner.
Dr. Chen also formerly worked at Shanghai Hile Bio-Technology Co., Ltd., as Director from 2014 to 2017, Hua Medicine Ltd., as Non-Executive Director from 2015 to 2022, Innovent Biologics, Inc., as Director, Adagene, Inc., as Director, Fog Pharmaceuticals, Inc., as Director, CStone Pharmaceuticals Co. Ltd., as Non-Executive Director from 2018 to 2021, Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd., as Director from 2019 to 2021, and FIL Capital Management (Hong Kong) Ltd., as Partner from 2008 to 2014.
Dr. Chen received his undergraduate degree in 1984 from Peking University and doctorate degree in 1991 from Université Catholique de Louvain.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
111, INC. CLASS A
7.69% | 27/02/2024 | 7 265 894 ( 7.69% ) | 4 M $ | 31/03/2024 |
Posizioni attive di Lian Yong Chen
Società | Posizione | Inizio |
---|---|---|
111, INC. | Director/Board Member | 01/05/2019 |
NEUSOFT XIKANG HOLDINGS INC. | Director/Board Member | 27/12/2019 |
CUTIA THERAPEUTICS | Chairman | 23/08/2019 |
OCUMENSION THERAPEUTICS | Chairman | 20/07/2021 |
Hua Medicine (Shanghai) Co., Ltd.
Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Director/Board Member | 01/04/2016 |
Cutia Therapeutics (Shanghai) Co., Ltd.
Cutia Therapeutics (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Cutia Therapeutics, Cutia Therapeutics (Shanghai) Co., Ltd. develops therapeutics to treat severe facial acne vulgaris. The private company is based in Shanghai, China. The Chinese company was founded in 2019. The CEO is Le Le Zhang. | Chairman | - |
Neusoft Medical Systems Co., Ltd.
Neusoft Medical Systems Co., Ltd. Medical SpecialtiesHealth Technology Neusoft Medical Systems Co., Ltd. engages in the research, development, manufacturing, and sale of large-scale medical diagnosis and treatment equipment and solutions as well as the provision of related services. Its products include computed tomography systems, magnetic resonance imaging systems, digital subtraction angiography systems, ultrasonic diagnostic equipment, positron emission tomography equipment, radiotherapy products, as well as in vitro diagnostic equipment and reagents. The company was founded on March 6, 1998 and is headquartered in Shenyang, China. | Director/Board Member | 28/03/2019 |
China Life Sciences Access Fund LP
China Life Sciences Access Fund LP Investment ManagersFinance China Life Sciences Access Fund LP is a venture capital fund that operates in the life sciences industry. The private company is based in George Town, Cayman Islands. | Corporate Officer/Principal | - |
Hua Medicine Technology (Hong Kong) Ltd. | Director/Board Member | 01/01/2015 |
░░░░░░ ░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Precedenti posizioni note di Lian Yong Chen
Società | Posizione | Fine |
---|---|---|
░░░ ░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Formazione di Lian Yong Chen
Peking University | Undergraduate Degree |
Université Catholique de Louvain | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 9 |
---|---|
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. | Health Technology |
HUA MEDICINE (SHANGHAI) LTD. | Health Technology |
INNOVENT BIOLOGICS, INC. | Health Technology |
ADAGENE INC. | Health Technology |
NEUSOFT XIKANG HOLDINGS INC. | Technology Services |
CSTONE PHARMACEUTICALS | Health Technology |
111, INC. | Distribution Services |
OCUMENSION THERAPEUTICS | Health Technology |
CUTIA THERAPEUTICS | Health Technology |
Aziende private | 13 |
---|---|
China Life Sciences Access Fund LP
China Life Sciences Access Fund LP Investment ManagersFinance China Life Sciences Access Fund LP is a venture capital fund that operates in the life sciences industry. The private company is based in George Town, Cayman Islands. | Finance |
Neusoft Medical Systems Co., Ltd.
Neusoft Medical Systems Co., Ltd. Medical SpecialtiesHealth Technology Neusoft Medical Systems Co., Ltd. engages in the research, development, manufacturing, and sale of large-scale medical diagnosis and treatment equipment and solutions as well as the provision of related services. Its products include computed tomography systems, magnetic resonance imaging systems, digital subtraction angiography systems, ultrasonic diagnostic equipment, positron emission tomography equipment, radiotherapy products, as well as in vitro diagnostic equipment and reagents. The company was founded on March 6, 1998 and is headquartered in Shenyang, China. | Health Technology |
Frontline Bioventures | Finance |
6 Dimensions Capital
6 Dimensions Capital Investment ManagersFinance 6 Dimensions Capital is an independent private equity firm headquartered in China. The firm was founded in 2017. | Finance |
Fog Pharmaceuticals, Inc.
Fog Pharmaceuticals, Inc. BiotechnologyHealth Technology Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA. | Health Technology |
TenNor Therapeutics Suzhou Ltd.
TenNor Therapeutics Suzhou Ltd. Pharmaceuticals: GenericHealth Technology TenNor Therapeutics Suzhou Ltd. manufactures pharmaceutical products. It specializes in research and development of new drugs for the treatment of digestive diseases caused by pathogens, including those resistant to available antibiotics. The company was founded by Zhen Kun Ma in 2013 and is headquartered in Suzhou, China. | Health Technology |
Engine Biosciences Pte Ltd.
Engine Biosciences Pte Ltd. BiotechnologyHealth Technology Engine Biosciences Pte Ltd. develops novel combinations of genes and drugs for therapeutic and industrial purposes. The company was founded by Timothy Lu and Jeffrey Lu and is headquartered in Singapore. | Health Technology |
Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd.
Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. Pharmaceuticals: MajorHealth Technology Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. engages in research and development of medical technology. The company was founded by Zhi Hong on April 19, 2018 and is headquartered in Shanghai, China. | Health Technology |
Tongrun Biomedicine (Shanghai) Co., Ltd.
Tongrun Biomedicine (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Tongrun Biomedicine (Shanghai) Co., Ltd. develops tumor immunotherapy drugs. The company is based in Shanghai, China. | Health Technology |
Hua Medicine Technology (Hong Kong) Ltd. | |
Hua Medicine (Shanghai) Co., Ltd.
Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Health Technology |
FIL Capital Management (Hong Kong) Ltd. | |
Cutia Therapeutics (Shanghai) Co., Ltd.
Cutia Therapeutics (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Cutia Therapeutics, Cutia Therapeutics (Shanghai) Co., Ltd. develops therapeutics to treat severe facial acne vulgaris. The private company is based in Shanghai, China. The Chinese company was founded in 2019. The CEO is Le Le Zhang. | Health Technology |
- Borsa valori
- Insiders
- Lian Yong Chen